Loading...
Loading...
Analysts at Credit Suisse downgraded BIND Therapeutics
BIND from Outperform to Neutral.
The price target for BIND Therapeutics has been lowered from $20 to $10.
BIND Therapeutics shares have dropped 40.43% over the past 52 weeks, while the S&P 500 index has gained 16.21% in the same period.
BIND Therapeutics' shares rose 0.90% to close at $6.72 yesterday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in